WALTHAM, Mass., Nov. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference in Boston, MA with a fireside chat on Wednesday, November 13, 2024, at 1:30 p.m. ...

WALTHAM, Mass., Oct. 29, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercialstage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2024 financial results and provide a business update on Tuesday, November 5, 2024. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, November 5, 2024 to discuss the Company's financial ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Sharon Klahre - Head, IR Michael Metzger - CEO Steve Closter - Chief Commercial Officer Keith Goldan - CFO Neil Gallagher - President, Head of Research and Development Conference Call Participants Malcolm Kuno - JPMorgan Kevin Sterling - Goldman Sachs Ernie Rodriguez - TD Cowen Brad Canino - Stifel Michael Schmidt - Guggenheim Ashiq Mubarack - Citi Kalpit Patel - B. Riley Justin Zelin - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other Ju ...

Exhibit 99.1 Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update – Axatilimab BLA in refractory chronic GVHD is under Priority Review; PDUFA action date of August 28, 2024 – – Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – – Pivotal AUGMENT-101 topline data from the mNPM1 AML cohort expected in 4Q24; potential sNDA filing in 1H25 – – Company to host a conference call today at 4:30 p.m. ET – WALTHAM, ...

Shares of Syndax Pharmaceuticals (SNDX) plunged in intraday trading Monday after the biopharmaceutical company reported that the Food and Drug Administration (FDA) delayed a decision on approving its experimental treatment for acute leukemia. CEO Says Earlier Trials 'Support Approval' Do you have a news tip for Investopedia reporters? Please email us at The Food and Drug Administration (FDA) delayed its approval for a leukemia drug from Syndax Pharmaceuticals after receiving more information from the compan ...

"plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materi ...

Syndax Pharmaceuticals (SNDX) closed the last trading session at $23.50, gaining 18.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $35.31 indicates a 50.3% upside potential. The average comprises 13 short-term price targets ranging from a low of $23 to a high of $45, with a standard deviation of $6.28. While the lowest estimate indicates a decline of 2.1% from the current price ...

WALTHAM, Mass., July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2024 financial results and provide a business update on Thursday, August 1, 2024. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, August 1, 2024 to discuss the Company's financial r ...

While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. Here's What You Should Know About Analysts' Price Targets They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other w ...